Russ Biagio Altman | |
|---|---|
 Altman in 2007 | |
| Born | |
| Education | Harvard College Stanford University |
| Scientific career | |
| Institutions | Stanford University |
| Thesis | Exclusion methods for the determination of protein structure from experimental data[1] (1989) |
| Doctoral students | Nicholas Tatonetti Olga Troyanskaya Soumya Raychaudhuri |
| External videos | |
|---|---|
 What really happens when you mix medications?, 14:41,TED talks[3] |
Russ Biagio Altman is an American professor ofbioengineering, genetics, medicine, andbiomedical data science (and of computer science, by courtesy) and past chairman of the bioengineering department atStanford University.
Altman holds an A.B. in biochemistry & molecular biology[4] fromHarvard College in 1983, a Ph.D. in medical information sciences from Stanford in 1989 and M.D. fromStanford Medical School in 1990.[1] After his internship at Stanford, he became board certified in 1991 in internal medicine and in clinical informatics in 2014. After a year of post-doctoral research, he joined the faculty as assistant professor in 1992. He became full professor in 2004, and was chair of the department of bioengineering from 2007 to June 2012.[2] He was the Kenneth Fong Professor of Engineering at Stanford, and an advisor to the Chan Zuckerberg Biohub from 2016- 2021. As of 2018, Altman was a founding co-editor of theAnnual Review of Biomedical Data Science.[5] As of 2021, Russ Altman was the lead editor.[6]
His primary research interests are in the application of computing and informatics technologies to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels. His lab studies how human genetic variation impacts drug response, helping start thePharmGKB project in 2000.[7] Other work focuses on the analysis of biological molecules to understand the actions, interactions and adverse events of drugs, publishing a database called FEATURE in 2003.[8][9] He helps lead an FDA-supported center for regulatory science and innovation (CERSI).[10] He chaired the Science Board advising the FDA Commissioner, serves on the NIH director’s advisory committee, and is co-chair of the IOM Drug Forum. He is an organizer of the annualPacific Symposium on Biocomputing. He co-founded Personalis, Inc. In 2011 along with three other faculty members includingEuan Ashley,Atul Butte, Michael Snyder and businessman John West.[11] In 2017, he started hosting a show onSiriusXM (Insight Channel 121) titled "The Future of Everything".[12] He is clinically active with a pharmacogenomics consultative service at Stanford Healthcare.
Altman received the U.S.Presidential Early Career Award for Scientists and Engineers (1997) and aNational Science Foundation CAREER Award (1996). He is a fellow of theAmerican College of Physicians (ACP), theAmerican College of Medical Informatics (ACMI), theAmerican Institute for Medical and Biological Engineering (AIMBE), and theAmerican Association for the Advancement of Science (AAAS). He is a member of theNational Academy of Medicine (formerly the Institute of Medicine) of the National Academies. He was president (2000 to 2002), founding board member, and aFellow of theInternational Society for Computational Biology (ISCB), and-president of theAmerican Society for Clinical Pharmacology & Therapeutics (ASCPT) from March 2013 to 2014.[13]
He received the Stanford Medical School graduate teaching award in 2000, and mentorship award in 2014.
In 2018, Altman was awarded the ISCB Outstanding Contributions Award.[14]
In 2020, Russ Altman received the ISCB Outstanding Contributions Award.[15]
In 2023, He won the Stanford Medicine Alumni Kornberg-Berg Lifetime Achievement Award.[6]
| Preceded by | President of the International Society for Computational Biology 2000 – 2002 | Succeeded by |
